Published on 28/10/2020 12:10:46 PM | Source: Reuters

Novartis, Molecular Partner team up on COVID-19 candidates

Posted in Top Stories| #World Market #COVID-19

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel 

Download Telegram App before Joining the Channel

ZURICH  - Novartis has licenced global rights to two Molecular Partners antiviral drugs that have potential to treat COVID-19 patients, the two companies said on Wednesday.

Molecular Partners will get an upfront payment of 60 million Swiss francs ($66.2 million), a potential milestone payment of 150 million francs, and a "significant royalty" on sales of the drugs called MP0420 and MP0423.


($1 = 0.9070 Swiss francs)


(Reporting by John Miller)